Search
Search Results
-
Therapeutic efficacy of an alpha-particle emitter labeled anti-GD2 humanized antibody against osteosarcoma—a proof of concept study
PurposeCurrent treatments for osteosarcoma (OS) have a poor prognosis, particularly for patients with metastasis and recurrence, underscoring an...
-
Imaging and dosimetry for alpha-particle emitter radiopharmaceutical therapy: improving radiopharmaceutical therapy by looking into the black box
Radiopharmaceutical therapy using α-particle emitting radionuclides (αRPT) is a novel treatment modality that delivers highly potent alpha-particles...
-
Alpha Particle–Emitting Radiopharmaceuticals as Cancer Therapy: Biological Basis, Current Status, and Future Outlook for Therapeutics Discovery
Critical advances in radionuclide therapy have led to encouraging new options for cancer treatment through the pairing of clinically useful...
-
Pre-clinical evaluation of biomarkers for the early detection of nephrotoxicity following alpha-particle radioligand therapy
PurposeCancer treatment with alpha-emitter-based radioligand therapies (α-RLTs) demonstrates promising tumor responses. Radiolabeled peptides are...
-
Protection from contamination by 211At, an enigmatic but promising alpha-particle-emitting radionuclide
Purpose211 At, a promising alpha-particle-emitting radionuclide, can easily volatilize and contaminate the environment. To safely manage this unique...
-
National Cancer Institute support for targeted alpha-emitter therapy
BackgroundRadiopharmaceutical targeted therapy (RPT) has been studied for decades; however, recent clinical trials demonstrating efficacy have helped...
-
Dosimetric impact of Ac-227 in accelerator-produced Ac-225 for alpha-emitter radiopharmaceutical therapy of patients with hematological malignancies: a pharmacokinetic modeling analysis
BackgroundActinium-225 is an alpha-particle emitter under investigation for use in radiopharmaceutical therapy. To address limited supply,...
-
Estimation of relative biological effectiveness of 225Ac compared to 177Lu during [225Ac]Ac-PSMA and [177Lu]Lu-PSMA radiopharmaceutical therapy using TOPAS/TOPAS-nBio/MEDRAS
AimOver recent years, [ 225 Ac]Ac-PSMA and [ 177 Lu]Lu-PSMA radiopharmaceutical therapy have evolved as a promising treatment option for advanced...
-
The Curies’ element: state of the art and perspectives on the use of radium in nuclear medicine
BackgroundThe alpha-emitter radium-223 ( 223 Ra) is presently used in nuclear medicine for the palliative treatment of bone metastases from...
-
A mesh-based model of liver vasculature: implications for improved radiation dosimetry to liver parenchyma for radiopharmaceuticals
PurposeTo develop a model of the internal vasculature of the adult liver and demonstrate its application to the differentiation of...
-
Production of [211At]NaAt solution under GMP compliance for investigator-initiated clinical trial
BackgroundThe alpha emitter astatine-211 ( 211 At) is garnering attention as a novel targeted alpha therapy for patients with refractory thyroid...
-
Quantitative SPECT/CT imaging of lead-212: a phantom study
BackgroundLead-212 ( 212 Pb) is a promising radionuclide for targeted therapy, as it decays to α-particle emitter bismuth-212 ( 212 Bi) via β-particle...
-
Development of [211At]astatine-based anti-CD123 radioimmunotherapy for acute leukemias and other CD123+ malignancies
Radioimmunotherapy (RIT) has long been pursued to improve outcomes in acute leukemia and higher-risk myelodysplastic syndrome (MDS). Of increasing...
-
Mono- and multimeric PSMA-targeting small molecule-thorium-227 conjugates for optimized efficacy and biodistribution in preclinical models
PurposePSMA (prostate-specific membrane antigen) is highly expressed on prostate cancer (PrCa) cells and extensively used as a homing target for PrCa...
-
Airborne respiratory aerosol transport and deposition in a two-person office using a novel diffusion-based numerical model
BackgroundThe COVID-19 pandemic was caused by the SARS-CoV-2 coronaviruses transmitted mainly through exposure to airborne respiratory droplets and...
-
KSNM60 in Non-thyroidal Radionuclide Therapy: Lea** into the Future
This year, the Korean Society of Nuclear Medicine (KSNM) is celebrating its 60th anniversary. Treatment, as well as diagnosis, has played a very...
-
Can current preclinical strategies for radiopharmaceutical development meet the needs of targeted alpha therapy?
Preclinical studies are essential for effectively evaluating TAT radiopharmaceuticals. Given the current suboptimal supply chain of these...
-
A GATE simulation study for dosimetry in cancer cell and micrometastasis from the 225Ac decay chain
BackgroundRadiopharmaceutical therapy (RPT) with alpha-emitting radionuclides has shown great promise in treating metastatic cancers. The successive...
-
Highlight selection of radiochemistry and radiopharmacy developments by editorial board
BackgroundThe Editorial Board of EJNMMI Radiopharmacy and Chemistry releases a biannual highlight commentary to update the readership on trends in...
-
Fibroblast activation protein targeted therapy using [177Lu]FAPI-46 compared with [225Ac]FAPI-46 in a pancreatic cancer model
PurposeFibroblast activation protein (FAP), which has high expression in cancer-associated fibroblasts of epithelial cancers, can be used as a...
